Key statistics
On Friday, Guardant Health Inc (5GH:DUS) closed at 84.84, -15.88% below its 52-week high of 100.85, set on Jan 22, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 82.36 |
|---|---|
| High | 84.84 |
| Low | 82.36 |
| Bid | 85.92 |
| Offer | 86.42 |
| Previous close | 85.18 |
| Average volume | 6.00 |
|---|---|
| Shares outstanding | 128.84m |
| Free float | 123.56m |
| P/E (TTM) | -- |
| Market cap | 12.67bn USD |
| EPS (TTM) | -3.21 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 18:32 GMT.
More ▼
Press releases
- Guardant Health to Participate in Upcoming Investor Conferences
- Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
- Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
- Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
- Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
- Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families
- Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.
- Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy
More ▼
